Course Overview



This course will be held again on
April 27 - May 1, 2020.

Information contained in this site is for the 2019 program.
Information for the 2020 program not yet available.

State-of-the-art approaches to prevention, diagnosis, and treatment of infectious diseases

This comprehensive CME program ensures attendees are current with state-of-the-art approaches to prevention, detection, diagnosis and treatment of infectious diseases. Updates, best practices and new guidelines are presented by nationally recognized ID experts and master clinicians. Education is practical and results driven:

  • Strategies for optimal decision-making in the prevention, diagnosis and treatment of infectious diseases
  • Newer antimicrobials and treatment strategies for highly resistant bacterial infections
  • State-of-the-art approaches to common infections
  • Clinical approaches to complex, rare, "don't-miss" infections
  • New and emerging infectious diseases
  • Update on antifungal diagnostics and therapy
  • Optimal management of Staph aureus infections (MSSA and MRSA)
  • Infections in persons with substance use disorders
  • What’s new in HIV management and prevention
  • Hep C treatment workshop (optional)
  • Musculoskeletal infectious diseases 

As revised treatment strategies, new diagnostic tests, and guidelines are presented, they are coupled with specific recommendations for incorporating these updates into your day-to-day work.  

Highlights of the 2019 Program

Expanded Case-Based and Problem-Solving Education 

The 2019 program features an expanded range of interactive, case-based and problem-solving education. The formats are engaging and attendees are encouraged to pose questions in larger sessions as well as one-on-one with the national experts who will be providing updates at this event.

Treating Highly Resistant Infections, including:

  • MRSA and vancomycin-intermediate Staph aureus (VISA)
  • Extended spectrum beta-lactamase (ESBL)-producing gram negative rods
  • Carbapenemase-producing gram negative rods, including the NDM-1 metallo-beta-lactamase-producing organisms
  • Vancomycin-resistant enterococci (VRE) 
  • Azole-resistant fungal infections

Common Infectious Diseases: Updates in Prevention, Diagnosis and Treatment

Updates to keep you current on new strategies, state-of-the-art practices, and the most recent guidelines to address:

  • Infections in immunocompromised hosts
  • Infections in pregnancy, including Zika
  • Infections in persons with substance use disorders
  • Infections of travelers and foreign-born persons
  • Systemic fungal infections
  • Native and device-related orthopedic infections
  • Native and device-related central nervous system (CNS) infections
  • Ear, nose and throat (ENT) and eye infections
  • Bronchiectasis and pneumonia
  • HIV and its infectious and noninfectious complications
  • PEP (Post-Exposure Prophylaxis) and PrEP (Pre-Exposure Prophylaxis) to prevent HIV infection
  • Sexually transmitted infections
  • Hepatitis C monoinfection and coinfection
  • Tick and mosquito-borne infections and zoonoses
  • Vaccines and vaccine-preventable infections
  • Clostridium difficile infection

Challenging, Rare, and Emerging Infectious Diseases

Comprehensive updates on:

  • Zika, Ebola, Middle Eastern Respiratory Syndrome (MERS), and other emerging infectious diseases
  • Re-emergence of vaccine-preventable diseases 
  • Pulmonary and extrapulmonary non-tuberculous (“atypical”) mycobacteria, including Mycobacterium chimaera
  • Candida auris infection
  • Infections in travelers and immigrants
  • Zoonoses—the old and the new

Clinical Decision-Making

Hear directly from world-renowned specialists and master clinicians on their approach and decision-making criteria for:

  • Selecting the best antimicrobial and duration of treatment
  • Utilizing newer diagnostic tests
  • Diagnosing the low-probability, high-impact infections
  • Rapidly detecting life-threatening infections
  • Determining when and how long to hospitalize in the treatment of infectious diseases
  • The outpatient transition: IV or oral?
  • Optimizing empiric antimicrobial therapy: what to start, when to narrow and when to stop  

Our talks and workshops incorporate safety, quality and practice improvement in infectious diseases, including:

  • Antimicrobial stewardship workshop (optional)
  • Infection control
  • Early inpatient ID consultations to reduce mortality, length of stay, and cost
  • Outpatient Parenteral Antibiotic Therapy (OPAT): best practices in program design and operation
  • ID for hospital medicine practitioners


In 2019, we offer two optional pre-course workshops, giving you the option of in-depth, small-group learning about important topics in ID.

Please note: Seating is limited, and each workshop is available on a first-come, first-served basis.

State-of-the-Art Treatment of Hepatitis C Virus (HCV)
Monday, April 22, 3:30 - 5:30 pm

HCV disease management continues to rapidly advance. This special program provides small group, interactive, intensive and practical education for clinicians who wish to provide care for HCV-infected patients. 

Highlights include:

  • Screening and testing for HCV infection, and staging of liver disease for the non-hepatologist
  • A comprehensive, targeted  review of the treatment options for patients with HCV infection according to their HCV genotype, treatment experience and disease stage
  • Best practices for patient assessment, treatment, monitoring, side-effect management, and HCV care after cure (follow-up and cancer screening)
  • Evolving strategies for management of  HCV and HIV coinfection 
  • Guidance for managing persons with HCV and substance use disorders

Participants will leave with specific recommendations to improve the clinical care of people infected with HCV.

Principles and Practices for an Antimicrobial Stewardship Program (ASP)
Monday, April 22, 3:30 - 5:30 pm

This special workshop provides evidence-based principles and strategies to:

  • Build the necessary infrastructure and implement aneffective ASP
  • Comply with the CDC’s seven core elements for hospital ASPs
  • Utilize and integrate the microbiology lab and pharmacy into a multidisciplinary ASP
  • Identify the ways in which antimicrobial stewardship leads to improved outcomes, including:
    • Lower antimicrobial costs
    • Decreased incidence of resistant bacterial and candidal infections
    • Ensured optimal antimicrobial dosing, administration and monitoring
  • Utilize national benchmarking data to judge program outcomes and success
  • Measure the impacts and improve the outcomes of stewardship interventions
  • Create training programs for ASP practitioners (physicians, physician extenders, nurses and pharmacists) in your institution
  • Recognize the role of rapid diagnostics with ASP oversight and interpretation